High materiality8/10
Why Is Cough-Focused Trevi Therapeutics Stock Skyrocketing On Thursday?
Why it may matterVerify against the original reporting
The confirmation of trial parameters supports potential positive outcomes, similar to past successes.
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Trevi's SSRE analysis confirms no change in CORAL trial sample size. CORAL trial targets idiopathic pulmonary fibrosis patients with chronic cough. Trial enrollment is 75% complete, results expected by first half of 2025. Positive SSRE outcome supports efficacy seen in previous CANAL trial. TRVI stock increased by 71.50% following announcement.
- Trevi's SSRE analysis confirms no change in CORAL trial sample size.
- CORAL trial targets idiopathic pulmonary fibrosis patients with chronic cough.
- Trial enrollment is 75% complete, results expected by first half of 2025.
- Positive SSRE outcome supports efficacy seen in previous CANAL trial.
- TRVI stock increased by 71.50% following announcement.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.